ERG expression in prostate cancer biopsies with and without high-grade prostatic intraepithelial neoplasia: a study in Jordanian Arab patients
Received 6 March 2019
Accepted for publication 15 April 2019
Published 22 May 2019 Volume 2019:11 Pages 149—155
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Jan Colli
Najla Aldaoud,1,2 Ashley Graboski-Bauer,3 Nour Abdo,4 Samir Al Bashir,1,2 Ashraf O Oweis,5 Hanadi Ebwaini,1 Yousef Hasen,1–2,6 Rami Alazab,7 Kiril Trpkov8
1Department of Pathology and Microbiology, King Abdullah University Hospital, Irbid, Jordan; 2Jordan University of Science and Technology, Irbid, Jordan; 3Department of Teacher Education, University of Texas, El Paso, TX, USA; 4Department of Public Health, Jordan University of Science and Technology, Irbid, Jordan; 5Division of Nephrology, Department of Medicine, Jordan University of Science and Technology, Irbid, Jordan; 6Attasami Diagnostic Center, Tripoli, Libya; 7Division of Urology, Jordan University of Science and Technology, Irbid, Irbid; 8Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
Background: High-grade prostatic intraepithelial neoplasia (HGPIN) is the most likely precancerous lesion for prostatic adenocarcinoma (PCa). Recent molecular studies have shown that HGPIN can harbor TMPRSS2-ERG fusion, a genetic marker also associated with PCa, which may provide an additional risk stratification tool for HGPIN, especially when present as an isolated lesion. Our aim was to assess the frequency of HGPIN and ERG expression in a cohort of prostatic needle core biopsies from Jordanian-Arab patients with PCa.
Materials and methods: We studied 109 needle core biopsies from patients with PCa. Clinical data, including age and preoperative prostate specific antigen (PSA) level, were obtained from patients’ medical records.
Results: HGPIN was present in 31 (28.4 %) of the 109 cases. Of the HGPIN cases, 13 (41.9%) expressed ERG immunostain. ERG expression in HGPIN was independent of patient age at presentation (P=0.4), pre-operative PSA (P=0.9), and the grade, using the novel Grade Groups (P=0.5).
Conclusion: The frequency of HGPIN in our cohort appears similar to the one found in the Western patient populations and demonstrates a comparable frequency of ERG expression in these lesions.
Keywords: high-grade prostatic intraepithelial neoplasia, prostate carcinoma, ERG, immunohistochemistry
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]